A Phase 4 interventional study of Tamsulosin and Finasteride in Prostatic Hyperplasia, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-09-19.
Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies testing tamsulosin in Prostatic Hyperplasia — 8 open to participants now, 8 under way, 1 of them phase 3. Tamsulosin · Prostatic Hyperplasia.
Among the 48 studies testing tamsulosin in Prostatic Hyperplasia, this one is the 14th largest by enrollment, is one of 3 that started in 1998, is one of 17 in phase 4, and was the 19th registered.
828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
Browse Prostatic Hyperplasia studies →8 of the 48 studies testing tamsulosin in Prostatic Hyperplasia are open now, in 3 countries. Recruiting first, the newest first:
Ain Shams University · Sites in Egypt
Ages 45+
Beni-Suef University · Sites in Egypt
Ages 50+ · Men only
Ankara Training and Research Hospital · Sites in Turkey
Ages 40–85 · Men only
Azienda Ospedaliero Universitaria Maggiore della Carita · Sites in Italy
Ages 40+ · Men only · Healthy volunteers
Il-Yang Pharm. Co., Ltd.
Ages 45+ · Men only
By country, each count listing its studies:
Tamsulosin: first FDA approval 1997 (FLOMAX). What it is approved for, and how studies give it, is on its page →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 50 Years to 80 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 3 started in 1998.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 403 is above the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 118 across the 48 interventional studies. Of the 35 that completed or were terminated, 12 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 48 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
18 studies in Prostatic Hyperplasia by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 18 finished, 3 (17%) have results posted.
Among the 18 studies in Prostatic Hyperplasia by Boehringer Ingelheim, this one is one of 3 that started in 1998, is one of 4 in phase 4, and was the 2nd registered.
Boehringer Ingelheim’s Prostatic Hyperplasia studies by the year they started, since 1998.
5 of the studies testing tamsulosin in Prostatic Hyperplasia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07870759Phase 3Il-Yang Pharm. Co., Ltd.Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia | 2027-08-31 |
| NCT07722884Ain Shams UniversityTamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH | 2027-01-01 |
| NCT07743034Mohsen PouraziziIris Structural Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients | 2027-04 |
| NCT07743060Mohsen PouraziziPupil Size and Choroidal Thickness Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients | 2027-04 |
| NCT07650968Beni-Suef UniversityTamsulosin Dose Escalation or Silodosin Switch Before Trial Without Catheter in BPH-Related Acute Urinary Retention | 2027-05 |
Add all 5 to your calendar (.ics) → With an account.
Among the 48 studies testing tamsulosin in Prostatic Hyperplasia, from their registry updates:
Among Boehringer Ingelheim’s 18 in Prostatic Hyperplasia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study to evaluate the therapeutic effect of tamsulosin and finasteride in symptomatic BPH patients, two medications indicated in BPH belonging to two different pharmacological classes, as evaluated from the point of view of patient's perception of his pathological condition and of the impact of the disease on general health and quality of life
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with known history or diagnosis at the time of the screening visit of the following conditions that could influence the end-points of the study:
Urological disturbances
Cardiovascular diseases - The following cardiovascular diseases if occurred in the last 6 months:
Neurological diseases
Hepatic or renal insufficiency
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tamsulosin · Drug: Placebo
Drug: Finasteride · Drug: Placebo
Change from baseline in Symptom Problem Index (SPI) by means of validated patient questionnaire
Time frame: Baseline, after 26 weeks of treatment
Change in Symptom Problem Index (SPI) - by means of validated patient questionnaire
Time frame: up to 52 weeks
Change in International Prostatic Symptom Score (IPSS)
questionnaire for the self-evaluation of urinary symptoms
Time frame: up to 52 weeks
Change in Qmax by means of free flow uroflowmetry
Time frame: up to 52 weeks
Number of patients who withdrew due to inefficacy
Time frame: up to 52 weeks
Number of patients with adverse events
Time frame: up to 54 weeks
Number of patients with abnormal changes in laboratory parameters
Time frame: up to 52 weeks
No study locations are listed for this record.
The record gives a start of Apr 1998 and a primary completion of Nov 2000. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tamsulosin